Bruce Halpryn Application PackageHalpryn Bruce M
Last Name First Name Middle Initial
1455 Ocean Drive, #1509 Miami Beach
Home Address City
Florida 33139-4141
State Zip Code
HomeWork
bmh3557@yahoo.com
Email Address
513-549-6484
Cellular
Cincinnati
Business Address
2356 Park Ave, #17
City
Ohio
State
45206
Zip Code
Eikonoklastes Therapeutics, Inc
Occupation:Business Name:
CEO, Board Chair
Please list your preferences in order of ranking [1] first choice [2] second choice, and [3] third choice. Please note
that only three (3) choices will be observed by the City Clerk’s Office. (Regular Boards of City)
Choice 1:
Choice 2:
Choice 3:
Historic Preservation Board
BOARD AND COMMITTEE
APPLICATION FORM
Note:If applying for the At-Large position of the Historic Preservation Board, please answer the below
questions:
Have you ever resided in one of the City's Historic Districts for at least one year?Yes
1455 Ocean Drive, #1509, Miami Beach, FL
33139
3/28/2019 12/12/2022
Address
From:
Dates
To:
If you answered "Yes", please indicate:
Professional License
No Professional Licenses Submitted.
Note:If you are seeking appointment to a professional seat (e.g. attorney, architect, etc.), you must attach a copy of
your currently effective corresponding professional license.
Pursuant to City Code section 2-22(4) a, b and c: Members of Agencies, Boards, and Committees shall be
affiliated with the city. This requirement shall be fulfilled in the following ways:
YesResident of the City for a minimum of six (6) months:
Demonstrate an ownership interest in a business established in the City for a minimum of six (6) months:No
AFFILIATION WITH THE CITY OF MIAMI BEACH
a.
● I am resident of:South Beach
Or
b.
"Ownership Interest" shall mean the ownership of ten percent (10%) or more (including the ownership of 10%
or more of the outstanding capital stock) in a business.
"Business" shall mean any sole proprietorship, sponsorship, corporation, limited liability company, or other
entity or business association.
c.Full-time employee of such a business (for a minimum of six months); and I am based in an office or
other location of the business that is physically located in Miami Beach (for a minimum of six months):No
Notwithstanding the requirements set forth herein, the qualified full-time employee of a business must be
approved by a 4/7th vote of the Mayor and City Commission.
NOTE: Members of Agencies, Boards, and Committees shall be required to demonstrate compliance with the City
affiliation requirements of section 2-22 (4) a and b of the Miami Beach City Code by executing an affidavit,
stipulating that they have met either (or both) of said affiliation requirements. The original affidavit shall be filled
with the Office of the City Clerk prior to being sworn in as a member.
Or
No● Have you ever been convicted of a felony:If yes, please explain in detail:
● Do you currently have a violation(s) of City of Miami Beach codes:No If yes, please explain in detail:
● Do you currently owe the City of Miami Beach any money:No If yes, please explain in detail:
● Are you currently serving on any City Boards or Committees:No If yes, which board?
● Are you presently a registered lobbyist with the City of Miami Beach?No
● I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
I am a serial entrepreneur with a passion for the Arts and Sciences. I have served on many non-profit arts
boards, many as the president of the board and/or chair of one or more of the board committees. I have just
been recognized by Philanthropy Miami and Miami City Ballet as a “Donor Next Door”
NOTE: IF APPOINTED, YOU WILL BE REQUIRED TO FOLLOW CERTAIN LAWS THAT APPLY TO CITY
BOARD/COMMITTEE MEMBERS. THESE LAWS INCLUDE, BUT ARE NOT LIMITED TO:
o Prohibition from directly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).
o Prohibition from contracting with the city (Miami-Dade County Code section 2-11.1).
o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office
(Miami Beach Code section 2-26)
o Requirement to disclose certain financial interests and gifts (Miami-Dade County Code section 2-11.1).
o Sunshine Law - Florida's Government-in-the-Sunshine Law was enacted in 1967. Today, the Sunshine Law
regarding open government can be found in Chapter 286 of the Florida Statutes. These statutes establish a basic
right of access to most meetings of Boards, Commissions, and other governing bodies of state and local
governmental agencies or authorities.
o Voting conflict - Form 8B is for use by any person serving at the county, city, or other local level of government on
an appointed or elected Board, Council, Commission, Authority, or Committee. It applies equality to members of
advisory and non-advisory bodies who are presented with a voting conflict of interest under Section 112.3143.
Florida Statutes.
● In what organization(s) in the City of Miami Beach do you currently hold membership in?
No Organization Information Submitted.
● List the address of all properties owned or in which you have an interest within the City of Miami Beach:
Property
Il Villaggio Condominium, 1455 Ocean Drive, #1509 Miami Beach, FL 33139
If so, which department and title?No● Are you now employed by the City of Miami Beach:
● Pursuant to City Code Section 2-25 (b):
Do you have a parent, spouse, child, brother, or sister who is employed by the City of Miami Beach?No
If "Yes", identify person(s) and department(s):
No relative's information submitted.
BOARD & COMMITTEE FINANCIAL ACKNOWLEDGEMENT STATEMENT
Acknowledgement of fines/suspension for Board/Committee Members for failure to comply with
Miami-Dade County Financial Disclosure Code Section 2-11.1(i)(2)
I understand that no later than July 1, of each year all members of Boards and Committees of the City of Miami
Beach, including those of a purely advisory nature, are required to comply with Miami-Dade County Financial
Disclosure Requirements.
One of the following forms must be filled with the City Clerk of Miami Beach, 1700 Convention Center Drive,
Miami Beach, Florida, no later than 12:00 noon of July 1, of each year:
1. A "Source of Income Statement;" or
2. A "Statement of Financial Interests (Form 1)¹ ;" or
3. A Copy of your latest Federal Income Tax Return.
Failure to file one of these forms, pursuant to the Miami-Dade County Code, may subject the person to a fine of no
more than $500, 60 days in jail, or both.
_____________________________
¹ Members of the Planning Board and Board of Adjustment will be notified directly by the State of Florida, pursuant
to F.S. §112.3145(1)(a), to file a Statement of Financial Interests (Form 1) with the Miami-Dade County Supervisor of
Elections by 12:00 noon, July 1. Planning Board and Board of Adjustment members who file their Form 1 with the
County Supervisor of Elections automatically satisfy the County’s financial disclosure requirement as a Miami Beach
City Board/Committee member and need not file an additional form with the Office of the City Clerk. However,
compliance with the County disclosure requirement does not satisfy the State requirement.
DIVERSITY STATISTICS REPORT
The following information is voluntary and has no bearing on your consideration for appointment. It is being asked to
comply with City diversity reporting requirements.
WhiteRace/Ethnic Categories
What is your race?
No details providedOther Description:
Gender:Male
Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino.No
Physically Challenged:No
I HEREBY ATTEST TO THE ACCURACY AND TRUTHFULNESS OF THE APPLICATION; AND I HAVE
RECEIVED, READ AND WILL ABIDE BY CHAPTER 2, ARTICLE VII, OF THE MIAMI BEACH CITY CODE,
ENTITLED “STANDARDS OF CONDUCT FOR CITY OFFICERS, EMPLOYEES AND AGENCY MEMBERS AND
ALL OTHER APPLICABLE COUNTY AND/OR STATE LAWS AND STATUTES ACCORDINGLY.”
I Bruce Halpryn agreed to the following terms on 12/12/2022 10:59:46 AM
Received in the City Clerk's Office by:
Name of Deputy Clerk Control No. Date
Board and Committee Application Checklist: Please ensure you have provided all information before applying or
reapplying to any Board and Committee.
YES
YES
YES
YES
I have answered all questions fully.
I have uploaded a current resume, photograph, and a copy of any applicable professional license.
I have completed and attached the Board & Committee Financial Acknowledgment Statement.
I have completed and attached the Diversity Statistics Report.
If you have any questions, please contact the Office of the City Clerk via email: BC@miamibeachfl.gov or
telephone: 305.673.7411
Note: Florida Statutes 119.071: The role of the Office of the City Clerk is to receive and maintain forms filed as
public records. If your home address, telephone numbers, and/or photograph are exempt from disclosure and you
do not wish your home address, telephone numbers, and/or photograph to be made public, please:
1) Use your office or other address for your mailing address;
2) Use your office or other telephone number for your contact number; and
3) Do not attach a photograph.
Bruce M. Halpryn, Ph.D.
1455 Ocean Dr., #1509
Miami Beach, FL 33139
513-659-4690
-----EDUCATION-----
Ph.D. in biology, State University of New York at Binghamton. June 1983
B.S. in biology, State University of New York at Stony Brook. May 1979
-----CURRENT POSITIONS------
Eikonoklastes Therapeutics, Co-founder, Chief Executive Officer and President, 6/2019-present.
Licensed a new state-of-the-art immunoconjugate technology from the Ohio State University targeting
tissue factor, which is only expressed on pathogenic cells but not on healthy cells. Our first targets will be
high unmet need, high morbidity and mortality conditions such as triple -negative breast cancer, ovarian
cancer, and metastatic melanoma. Once an adequate safety profile has been established, we intend to
advance into less dire, non-oncology indications such as endometriosis. We are presently closing out our
seed round of $2.5M and will be initiating our Series A round of $5 -7M in Q2/3 2020. We expect to
initiate first-in-human clinical trials in Q2/2021.
Ohio I-CORPS Program, Adjunct Instructor, 6/2017-present. Instructor and mentor for academic life
science programs in the state of Ohio transitioning from an educational institution environment to a
bonafide commercial startup. Provide formal training in Business Model Generation and Value Proposition
Design and practical coaching on what it takes for Regulatory Agency approval and Commercial Success.
Larta Institute, Senior Advisor, Life Sciences and Open Innovat ion, 2007-present. Larta’s mission is
connecting people to drive innovation. Larta magages one of the the nation’s largest innovation pipelines.
They drive the success of technology companies by connecting them with the right people, partners and
capital. Their commercialization services help governments, universities and corporations accelerate
technology transfer and expedite its movement into commercialization. In that vein, I am assigned as a
confidential advisor by Larta to several promising start up companies each year, to help them hone their
pitch to investors, to advise them on their strategic approach to development and interaction with regulatory
agencies, to make appropriate introductions on their behalf to sources of capital and/or potential partners or
advisors to expedite their movement into commercialization. To date I have advised companies with
inventions in biotechnology, new drug candidates, diagnostics, and medical devices. With help from some
of my advice and connections, many of my start ups have reached fruition by either being bought out,
licensed or partnered by larger companies, or found Venture Capital and/or Angel funding to continue
development on their own. In December 2014, I was sought out by the government of Malaysia to serve as
Program Advisor to several of the inaugural companies in the Bioincubator they are establishing.
---- PREVIOUS EXPERIENCE-----
Myonexus Therapeutics, Inc. Co-Founder, Chief Operating Officer, and board Secretary 2/2017 -
4/2019. Myonexus Therapeutics was a clinical stage gene therapy company developing first ever
treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C. Led progression of
lead candidate from lab to first-in-human clinical studies and consequent acquisition by Sarepta (for total
consideration of up to $600M) in under 2 years. Clinical studies I designed and initiated showed
substantial expression of the missing critical protein in muscle cell biopsies of treated children, and
translation of that expression into significant and continuing improvement in muscle function at 9 months,
compared to a >5% decline in muscle function in historical controls over the same time period. This study
is still ongoing and is expected to show substantial restoration of muscle function approaching normal
healthy levels.
N8 Medical/Kinnear Pharmaceuticals, Chief Operating Officer, 2014 -2016. N8 Medical is a
preclinical-stage pharmaceutical company developing innovative therapeutics based on a novel , proprietary
class of small molecule drug candidates known as ceragenins or Cationic Selective Antimicrobials. Current
active preclinical programs include: 1) an inhaled anti-infective for cystic fibrosis, 2) a next generation
bone graft substitute, 3) an oral mucositis therapeutic for head and neck cancer patients, 4) an inflammatory
bowel disease (“IBD”) therapeutic, and 5) a multiple myeloma therapeutic. After successful spinout of the
medical device coatings business, multiple programs were successfully brought to the IND stage; however,
in Q1 2016, operations were suspended to divert precious resources to supporting IP infringement
litigation.
Procter & Gamble Global One Health Sector, Sr. Director, Technology Development, Intellectual
Property Management, Open Innovation (Connect + Development), IP & Technical Due Diligence,
August 2009 to 2013. Technology responsibilities included leadership of the group responsible for the
innovation pipeline for our global OTC business including incremental product lifecycle innovations,
transformative products and disruptive new business opportunities amounting to >$100M of new business.
Several of these opportunities entered the market place in 2014 + 2015, with life cycle improvements
continuing to feed the market. Also led a team of patent agents and corporate patent attorneys in
management of the One Health Sector (Personal Health (OTC), Pet Care , Oral Care) patent portfolio and
provided IP strategy input into current portfolio, development projects, input into consideration of outside
opportunities and monitoring for infringement of our IP. Worked with Commercial, R&D, Product Supply,
Legal, IP, Tax, Finance, etc, led the open innovation “connect + develop” effort for global One Health
Sector including identifying, validating, and assessing outside opportunities and development of new tools
and procedures to increase the effectiveness and effic iency of these efforts. The processes developed have
been considered the “Gold Standard” in P&G and have been rolled out across the entire P&G company to
every business unit. Personally led all of the key IP & Technical Due Diligence reviews for the One Health
Sector’s outside opportunities as well as for our Future Works health care related opportunities. Trained
others to provide supplemental capability to lead due diligences as licensing increases. Served as internal
corporate consultant for IP & Technical Due Diligence efforts across all business units globally. Served as
the representative on the term sheet and contract negotiation teams for outside One Health opportunities
validated by due diligence as the representative looking our for all of the technical community’s (R&D,
Product Supply, etc) concerns. Additional responsibilities include: P&G chief technical liaison to Swiss
Precission Diagnostics our JV consumer diagnostics company; Secondee to Triathalon Ventures to oversee
our VC investment and identify appropriate opportunites for P&G to access, Managed the Due Diligence
process that enabled our JV with Teva Pharmaceuticals to reach closing.
Procter & Gamble Pharmaceuticals (formerly Norwich Eaton Pharmaceuticals), Director Connect &
Development/IP & Technical Due Diligence, 2005 – August 2009. When Pharmaceuticals decided to
close its internal research labs, I was asked to create a state of the industry Open Innovation Organization,
corresponding tools and best practices to build on th e IP & Technical Due Diligence Capabilities I already
created. The capability created resulted in P&GP indentifying, validating, conducting due diligence and
then successfully negotiating and closing on 3-4 opportunities a year. Created tools to ensure all due
diligences were evaluated on a consistant basis so that various internal and external opportunities could
have their risks and potential evaluated and compared on a comparable basis. Personally led all of the key
due diligences and represented R&D on the contract negotiating teams. When P&G decided to divest
pharmaceuticals, I was asked to design and then lead the due diligence process for this divesture. The
electronic data room was the largest ever in Intralinks history before or since. Despite the enormity of the
data base, the data was organized in a fashion that there were few questions on where to find things. At one
point I managed over 550 people with access to the electronic data room, all with different individual levels
of clearance. I managed all of the follow up technical discussions and questions. Pharmaceuticals was
successfully divested for $3.1B.
Procter & Gamble Pharmaceuticals, Director, Early Phase New Drug Development, 1995 to 2005.
Responsible for all Rx drug development projects in the portfolio from the pre -IND phase through proof-
of-concept and/or dose ranging, and co-responsible for the design of the phase III programs. This include d
internally generated projects as well as acquisitions and partnerships. Responsible for development
programs in heart failure, osteoporosis, osteoarthritis, anti-angiogenesis, upper respiratory, hormone
replacement, diabetes and migraine. Responsible for the total strategic direction of these programs and
matrixed multidisciplinary teams (e.g., Clinical, Regulatory, Toxicology, Chemical Development, Dose
Form Development, Finance, etc.) with direct reporting responsibility to me for e ach of these programs.
Complete responsibility and authority (within an approved budget) for the direction of the programs.
Responsible for training future project leaders to assume responsibility for leading individual programs.
An additional major responsibility included personally leading the technical due-diligence “swat teams” on
all potential in-licensing and partnering opportunities and advising internal project teams on managing
technical due diligence for out licensing and partnering opportunities. This required creating procedures
for the conduct and communication of due dilig ences without “poisoning” internal personnel from being
able to pursue competitive approaches to the same target. Responsibilities were also expanded to do initial
technical evaluations of “non-focus area” opportunities that had been identified. After the acquisition of
Groupo Vita Pharmaceuticals in Barcelona, I had transitional responsibility for indoctrinating the R&D
personnel into the P&G policies, procedures and culture.
Procter & Gamble Pharmaceuticals, Associate Director Cardiac Drug Development/Project Leader
Heart Failure Development Program, 1995 . Led team that prepared IND for second generation
inotrope/neurohumoral modulator. Supervise associate project leaders on other cardiac drug development
programs including arrhythmias, hypertension, cardioprotection/reperfusion injury. Had full responsibility
and authority for design and execution of cardiac programs within budget limitations. Responsibility
covers designing key animal studies to provide evidence that research lead has basis for marketplace
superiority, designing clinical program and product development support for clinical development program
from IND to NDA/PLA. Responsible for leading team to find partner for CHF development program.
Lead technical and market assessment of potential acquisitions and partnership opportunities for cardiac
and non-cardiac drugs. Additional responsibilities included design of clinical program and study protocols
for upper respiratory projects.
Procter & Gamble Pharmaceuticals, special assignment European Subsidiaries’ Regulatory Affairs,
1994-1995. Was sent to U.K. on special assignment to manage Regulatory Affairs organizations of
P&GP’s subsidiaries in Europe. Developed proposal, since implemented, for reporting relationships back
into European headquarters and into world-wide headquarters in Cincinnati as a result of new European
pharmaceutical legislation. Provided Regulatory Affairs input to strategy for expansion of pharmaceuticals
into white space markets in eastern Europe. Provided the regulatory support to allow initiation of
osteoporosis clinical trials in Russia. Created regulatory strategy for registration of ulcer “triple therapy” in
Europe.
Procter & Gamble Pharmaceuticals, special assignment Re-engineering of Pharmaceutical
organization for Time Based Competition, summer 1993. In a Boston Consulting Group facilitated re-
engineering of the pharmaceutical division to increase Time Based Competition, I was responsible for
leading the team that redefined the roles, responsibilities and reporting relationships of development project
teams, project leaders, core team members, functional managers and top management. Initial assessment, 1
year later, has demonstrated an increased focus on project priorities as opposed to functional prio rities.
Key measures of speed have improved 20 -40% from baseline. Projects now have better defined strategies,
and have success criteria, and “go/no go” decision points built into the project plans.
Procter & Gamble Pharmaceuticals, Section Head Cardiac Drug Development. 11/90-6/93. Overall
leadership responsibility for international clinical development programs for heart failure. Led
multidisciplinary teams that prepared and filed 2 IND's and European equivalents in France, Germany, and
England. Extensive interaction with the regulatory agencies and key thought leaders has been a key aspect
of position's requirements. Led projects through end of phase II at which time compounds were
discontinued. Led the class III antiarrhythmic “backup” program through the research to development
transition. Also responsible for leading the "due diligence" review of regulatory and technical documents
during acquisitions of Minipress, Minipress XL, Ziac, and Zebeta. Acted as technical Brand
Manager for these marketed products until product was returned to Pfizer in case of Minipress or a
replacement manager could be trained in the case of Ziac/Zebeta.
Norwich Eaton Pharmaceuticals, Staff Scientist . 6/86-11/90. Established a new lab for the chronic
instrumentation and monitoring of hemodynamic variables in conscious dogs. Collaborated in
development of new models of heart failure for testing of new inotropic compounds. Directly supervised
all in-vivo testing of potential cardiotonic agents. Chief scientist responsible for pre clinical pharmacology
on digitalis analogs project. Project leader of digitalis analog progression team.
National Research Council at NASA/Ames Research Center, Research Fellow. 6/83-6/86. Managed
a research team investigating the cardiovascular de-conditioning effect seen as a result of the micro-gravity
environment during space flight and as a result of ground based s imulations of low gravity. I also
participated in a study on the effect of chronic orthostatic and antiorthostatic hypokinesia on trabecular
bone formation in rhesus monkeys. I was co -investigator on the cardiovascular experiments flown aboard
the U.S./U.S.S.R. joint space flights; Cosmos 1514 and Cosmos 1667. I was responsible for the analysis
and interpretation of the cardiovascular flight data and ground based simulations. As part of this work I
developed specialized surgical and training techniques in order to conduct long-term chronic
experimentation in non-human primates. I was responsible for the implementation and physiological
evaluation of a completely implantable telemetry system that allows simultaneous monitoring of: multiple
blood pressures; cardiac output; temperature; and EKG in unrestrained animals.
NASA Graduate Student Training Grant, Pre-doctoral Fellowship. 12/79-6/83. I was responsible for
the development and implementation of long -term (two weeks) continuous (24 hours/day) monito ring
capabilities of cardiovascular variables. This monitoring capability enabled me to characterize the daily
changes that cardiovascular variables undergo, and to establish baseline values for heart rate, blood
pressure, cardiac output, stroke volume, and total peripheral resistance used by NASA as ground based
controls for the joint U.S. /U.S.S.R. Cosmos space flights. This work included conducting ground based
controls establishing pressure-flow relationships to the brain during control and space flight simulations. I
created software for the accurate micro-computer resolution of pulsatile physiological waveforms as well as
specifying programs for real time data acquisition and reduction on a mini -computer. I was responsible for
the verification of new instrumentation designed for the chronic measurement of carotid blood flow and
pressure during space flight.
Tri-Tonics Corporation, physiological consultant. I designed studies to evaluate the safety of various
electronic animal training devices. I supervised the implementation of these safety studies as well as
analyzed and interpreted the results. Outcome of clinical studies to evaluate effectivenss and safety of anti-
bark collars proved pivotal for defending against animal cruelty litigation.
Suntext Corporation, independent contractor. I wrote the text and questions for the cardiovascular and
renal physiology sections of a computerized package to study for the medical boards.
Primate Products Incorporated, consultant. Helped in the design and implementation of a rhesus
restraint system used to fly monkeys aboard the Space Shuttle as part of the King Louis project. As part of
this project, I helped design a software package to control and record data from a psychomotor panel used
for behavioral enrichment while the monkey was in the restraint system.
Mission College, physiology instructor pool. Taught anatomy and physiology classes to community
college students on an as needed basis.
Palmer Station, Antarctica. I was part of a two man team investigating thermoregulation and
cardiovascular circadian rhythms in Adelie penguins. Through the use of various pharmacological nerve
blocks and varying environmental conditions, we elucidated the neural mechanisms of blood flow control
to the uninsulated flipper, foot and beak of the penguin. We also determined the relative importance of
various body sites in the penguins' thermoregulation. We were the first investigators to document a
circadian rhythm of body temperature in Antarctic penguins during the continuous light of the austral
summer.
----COMMUNITY SERVICE----
Ex-President, Board of Trustees, concert:nova – Current Chair of Governance and Marketing committees
Board of Trustees, Cincinnati Ballet – previously chair of Artistic + Marketing committees. Passionate
about the dancers and the art form. Led numerous initiatives to support dancers such as a board mentorship
program for the dancers, dancer relations activities, dancer sponsorship program, etc.
President, Board of Trustees, FotoFocus – transformed the board from predominantly a formality, to
leading the creation of the organization’s Vision, Values, Mission and Stragety. Fotofocus has now grown
to the largest photography and lens-based art biannual in the country. The organization is getting national
and international attention for the quality of the curation of there shows and th e educational function they
are providing about photography as an art form.
Friends of Photography, Cincinnati Art Museum – Support of curator and mission to build a world class
photography collection and educate the public of importance of photography as an art form.
-----HONORS AND AWARDS-----
NASA Certificate of Appreciation, 1986 (for contributions to the U.S./ U.S.S.R. Cosmos 1667 Spaceflight
Mission).
NASA Certificate of Appreciation, 1984 (for contributions to the U.S. / U.S.S.R. Cosmos 1514 Spaceflight
Mission).
National Research Council (NRC) Fellowship, 1983-1986.
NASA Graduate Student Training Grant, 1980-1983.
Congressional Antarctic Service Medal, 1982 (in recognition of contributions to scientific research in
Antarctica).
State University of New York research assistantship, 1979 -1980.
Regents Scholar, State of New York, 1975-1979.
Board of Directors, Our Health Center - a non-profit community health clinic, 1982-1984.
Vice Chairman of the Board, concert:nova 2009-present
Board of Directors, Cincinnati Ballet 2011-present
-----PUBLICATIONS-----
Halpryn, Bruce M., E. Cabrera, V. Fulton, R. Fulton, T. Ogerau, S. Fenard, A. Baggioni, and Y. Chang .
LND 796, An Inotropic Steroid With Improved Separation Of Eff icacy From Toxicity Compared To
Digoxin. Cardiovascular Drugs and Therapy (submitted)
Capasso, Joseph M., B. Halpryn, L.M. Quattrocci, G. Olivetti, P. Anversa). Response Of The
Hypertensive-Diabetic Rat Myocardium To 10 Weeks Of Oral Digoxin. American J ournal of Physiology
(submitted)
Halpryn, Bruce M., R. Fulton, V. Fulton, T. Ogerau, S. Fenard, A. Baggioni, J. Koenig, Y. Chang . LND
796, A New, Safer Inotropic Steroid. The FASEB Journal (in -press)
Capasso, Joseph M., B. Halpryn, L.M. Quattrocci, G. Olivetti, P. Anversa (1988). Effects of Digoxin on
Global Cardiac Function of Hypertensive-Diabetic Rats. The Pharmacologist 30 (3): A41
Halpryn, Bruce M., R. Fulton, V. Fulton, R. Panasevich, T. Ogerau, S. Fenard, A. Bagioni, J. Koenig, Y.
Chang (1987). Activity of LND 623, a new inotropic steroid, in dogs. The Pharmacologist 29 (3): 135
Halpryn, Bruce M., R. Fulton, V. Fulton, R. Panasevich, T. Ogerau, S. Fenard, A. Baggioni, J. Koenig, Y.
Chang (1987). Activity of LND 623, a new inotropic steroid, in dogs. Proceedings of the Xth International
Congress of Pharmacology, Sydney.
Arnaud, Sara B., P. Patterson-Buckendahl, B.M. Halpryn, C. Maese, B.A. Harris, E. Morey-Holton, C.E.
Cann (1986). Endogenous Cortisol and serum osteocalcin in rhesus monkeys during simulated
weightlessness. Journal of Bone and Mineral Research 2 (suppl. I): 365.
Sandler, Harold V., Krotov, J., Hines, V., Magedov, B. Benjamin, A. Badakeva, B. Halpryn and H. Stone
(1985). Cardiovascular Results from a Rhesus Monkey Flow aboa rd the Cosmos 1514 Spacecraft. J. Avait
Space and Environ. Med.
Krotov, V., V. Magedov, H. Sandler, J. Hines, B. Benjamin. B. Halpryn, V. Krilov, N. MIlonov (1985).
Vosmoshmost registratziy ekstravasculyarmin arterialmovo davlana ee kravatok oo obezyan v
khronicheskom experimente (The possibliity of measuring pressure and flow extravascularly during
chronic experiments using monkeys). Bull. Exp. Biol. and Med. (in Russian).
Krotov, V., H. Sandler, A. Badakeva, J. Hines, A. Nazin, B. Halpryn (1985). Izucheniye terialnovo
davleniye uu skorosti krovotok oo obenzyaniy v kosmicheskom palyote (Changes in arterial pressure and
blood flow in a monkey during space flight). Proceedings of the All Union Conference on Aviation
Medicine June 1986, Kelyge, USSR.
Sandler, Harold, J. Hines, B. Halpryn (1985). Cosmos 1667 Cardiovascular Measurements - Experiment
Management Plan. NASA Technical Document.
Halpryn, Bruce M., E. Waterman, H. Sandler (1985). Effects of Various Restraint Chairs on Heart
Response in Rhesus Monkeys. The Physiologist 28 (4):365.
Halpryn, Bruce M. (1985). Biotelemetry Monitoring Systems. Laboratory Animal 14(6):21.
Halpryn, Bruce M., Paul Houghton (1984). The Pole and Collar Training Technique for Restraining
Rhesus Monkeys. NASA Technical Video.
Sandler, H., Lowell Stone, John W. Hines, Bruce Benjamin, Bruce Halpryn (1984). Preliminary Science
Report for Cosmos 1914 Primate Cardiovascular Experiment. NASA Technical Document.
Sandler, H., H. Lowell Stone, John W. Hines, Bruce Be njamin, Bruce Halpryn (1984). Preliminary
Science Report for Cosmos 1514 Primate Cardiovascular Experiment. NASA Technical Document.
Halpryn, Bruce M. (1983), Circadian Hemodynamics i the Rhesus Monkey: A Nervous Compensation to
Maintain Cerebral Blood Flow in the Upright Monkey at Night? Ph.D. Thesis.
Halpryn, Bruce M., David Murrish, Frank Sulzman, Harold Sandler (1983). Circadian Hemodynamics in
the Upright Sleeping Rhesus Monkey: A Sympathetic Nervous Compensation to maintain Cerebral Blood
Flow? The Physiologist 26(4):A76.
Halpryn, Bruce M., Paul Tirrell, Dave Murrish (1982). Circadian Rhythms in the Body Temperature of
Adelie Penguins. The Antarctic Journal of the United States 17(5):182
Halpryn, Bruce M., Dave Murrish, Frank Sulzman, Harold Sandler (1982). Cardiovascular Circadian
Rhythms in Rhesus Monkeys. The Physiologist 25(4): 189 Abst. 2.3.